USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing ...

Roche sees significant potential in the growing obesity market, estimating it could exceed $100 billion by 2030. During its ...

Johnson & Johnson has halted its plan to implement a 340B rebate model after the Health Resources and Services Administration ...

Following a positive a positive European Medicines Agency recommendation in July, the European Commission (EC) has now ...

Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of ...

ARS Pharmaceuticals' Neffy, the first needle-free epinephrine nasal spray, is poised to significantly impact the treatment of ...

Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the ...

Rivus Pharmaceuticals announced new Phase IIa HuMAIN study data for HU6, its investigational treatment for obesity-related ...

Recipharm and Exela Pharma Sciences have formed an exclusive strategic alliance to expand sterile manufacturing capabilities ...

Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing ...

The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will ...

Germany-headquartered CNS drug specialist Neuraxpharm Group today announced the launch of Neuraxpharm Middle East to cover ...